Equity Research firms currently have a positive stance on shares of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.50. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $5.25 on a short term basis.
At the time of writing, the stock was trading at $2.38. This represents a change from the opening price of 3.03%. In terms of performance, year to date, the stock is -46.76%. The monthly stock performance comes in at -4.08%. For the quarter, shares are performing at -14.34%. Weekly performance analysis shows the equity at -0.80%.
In taking a look at technical levels, shares are trading -2.16% away from the 50 day simple moving average and -16.38% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -70.98% away from it’s 52- week high and 17.24% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, HTG Molecular Diagnostics, Inc.’s RSI stands at 50.53. In looking at volatility levels, the shares saw weekly volatility of 6.48% and 6.89% over the past month.